Xilio Therapeutics/$XLO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xilio Therapeutics
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Ticker
$XLO
Sector
Primary listing
Employees
76
Headquarters
Website
XLO Metrics
BasicAdvanced
$49M
-
-$7.73
-0.02
-
Price and volume
Market cap
$49M
Beta
-0.02
52-week high
$9.25
52-week low
$6.68
Financial strength
Current ratio
2.577
Quick ratio
2.533
Long term debt to equity
15.907
Total debt to equity
19.715
Profitability
EBITDA (TTM)
-40.441
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-80.05%
Operating margin (TTM)
-95.92%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
-23.24%
Return on equity (TTM)
-132.53%
Valuation
Price to revenue (TTM)
0.878
Price to book
1.09
Price to tangible book (TTM)
1.09
Price to free cash flow (TTM)
-6.973
Free cash flow yield (TTM)
-14.34%
Free cash flow per share (TTM)
-1.216
Growth
Revenue change (TTM)
589.88%
Earnings per share change (TTM)
-49.25%
3-year earnings per share growth (CAGR)
-44.44%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xilio Therapeutics stock?
Xilio Therapeutics (XLO) has a market cap of $49M as of April 02, 2026.
What is the P/E ratio for Xilio Therapeutics stock?
The price to earnings (P/E) ratio for Xilio Therapeutics (XLO) stock is 0 as of April 02, 2026.
Does Xilio Therapeutics stock pay dividends?
No, Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders as of April 02, 2026.
When is the next Xilio Therapeutics dividend payment date?
Xilio Therapeutics (XLO) stock does not pay dividends to its shareholders.
What is the beta indicator for Xilio Therapeutics?
Xilio Therapeutics (XLO) has a beta rating of -0.02. This means that it has an inverse relation to market volatility.